130907-59-4

Basic information

• Product Name: 3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one
• Synonyms: 3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one
• CAS NO: 130907-59-4
• Molecular Weight: 272.301
• Mol File: 130907-59-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one(130907-59-4)
• EPA Substance Registry System: 3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one(130907-59-4)

Safety Data

• Hazardous Substances Data: 130907-59-4(Hazardous Substances Data)

Upstream product

• 108-73-6 3,5-dihydroxyphenol 
• 1505-50-6 3-(4-Methylphenyl)propanoic acid 
• 104-87-0 4-methyl-benzaldehyde 
• 128837-25-2 1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]ethan-1-one 

Relevant articles and documents

Quinoid dihydrochalcone dicarbonyl glycoside compound with glucose on A ring, preparation method and neuroprotective activity thereof

The invention discloses a class of quinoid dihydrochalcone C-glycoside compounds with glucose on a ring A, a preparation method and anti-cerebral ischemia injury activity thereof, wherein the compoundhas a structure represented by a general formula (I). The preparation method of the compound comprises the following steps: (1) synthesizing a 2,4,6-trihydroxy dihydrochalcone compound; (2) synthesizing a 2,4,6-trihydroxy-3,5-diglucosyl dihydrochalcone C-glycoside compound; and (6) synthesizing a class of quinoid dihydrochalcone C-glycoside compound with glucose in the A ring. The compound disclosed by the invention is simple in preparation method and has a remarkable effect of resisting cerebral ischemia injury.

Targeting type 2 diabetes with c-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (sglt2) inhibitors: Synthesis and biological evaluation

Inhibiting glucose reabsorption by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a relatively new strategy for treating type 2 diabetes. Selective inhibition of SGLT2 over SGLT1 is critical for minimizing adverse side effects associated with SGLT1 inhibition. A library of C-glucosyl dihydrochalcones and their dihydrochalcone and chalcone precursors was synthesized and tested as SGLT1/SGLT2 inhibitors using a cell-based fluorescence assay of glucose uptake. The most potent inhibitors of SGLT2 (IC50 = 9.23 nM) were considerably weaker inhibitors of SGLT1 (IC50 = 10.19 μM). They showed no effect on the sodium independent GLUT family of glucose transporters, and the most potent ones were not acutely toxic to cultured cells. The interaction of a C-glucosyl dihydrochalcone with a POPC membrane was modeled computationally, providing evidence that it is not a pan-assay interference compound. These results point toward the discovery of structures that are potent and highly selective inhibitors of SGLT2.